Moderna’s potential vaccine to prevent Covid-19 which was first reported to be appearing to be safe back in mid-May, offering a glint of hope, has just been reported by CNBC to have produced neutralizing antibodies in all 45 patients in its early stage human trial.
- Moderna’s potential vaccine to prevent Covid-19 produced neutralizing antibodies in all 45 patients in its early stage human trial, according to newly released data.
- The findings provide more promising data that the vaccine may give some protection against the coronavirus.
At 5pm EST, CNBC released a report that started with the opening paragraphs as follows:
Moderna’s potential vaccine to prevent Covid-19 produced a “robust” immune response in all 45 patients in its early stage human trial, providing more promising data that the vaccine may give some protection against the coronavirus, according to newly released data published Tuesday evening in the peer-reviewed New England Journal of Medicine.
All 45 patients produced neutralizing antibodies, which scientists believe are important for gaining protection against the virus. In the trial, each participant received a 25, 100 or 250 microgram dose, with 15 people in each dose group. Participants received two doses of the potential vaccine.
After two vaccinations, the vaccine elicited a “robust” immune response in all participants in all dose cohorts, Moderna said. The company said the levels of neutralizing antibodies in patients in the high dose group were fourfold higher than in recovered Covid-19 patients.
Moderna’s stock rose more than 9% in after-hours trading on the news.
The news could help to push the bulls back into full control on Wall Street whereby they are otherwise vulnerable to bank's guidance and earnings this week.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.